Sermorelin CJC-1295 are growth hormone secretagogues, but they differ in half-life, FDA status, and research dosing. Learn how they compare and stack safely.
Sermorelin and CJC-1295 are synthetic peptides that stimulate growth hormone release, but they are not interchangeable. Sermorelin is a short-acting GHRH analog, while CJC-1295 is a longer-acting modified version. Neither is approved for general human use in the United States, and both are sold for research purposes only.
What Are Sermorelin and CJC-1295?
Sermorelin is a 29-amino-acid peptide that copies the first 29 amino acids of natural growth hormone-releasing hormone (GHRH). The FDA once approved sermorelin as a diagnostic agent for pediatric GH deficiency, but that product is no longer marketed in the US.
CJC-1295 is a modified GHRH analog with four amino acid substitutions that make it resistant to enzymatic breakdown. There are two main forms: CJC-1295 with DAC (drug affinity complex) and CJC-1295 without DAC, often called mod GRF(1-29).
Both peptides ultimately increase GH release from the pituitary gland, but their duration of action varies dramatically. Natural GHRH is released in pulses, especially during deep sleep, and these peptides attempt to mimic or extend that signal.
Key Differences: Half-Life, Dosing, and FDA Status
The biggest practical difference between sermorelin and CJC-1295 is how long they remain active. Sermorelin is cleared from the bloodstream within minutes, while CJC-1295 with DAC can persist for days.
| Compound | Half-Life | FDA Status | Typical Research Dose |
|---|---|---|---|
| Sermorelin | 10–20 minutes | Not currently approved for human use | 100–200 mcg subcutaneously at night |
| CJC-1295 with DAC | 6–8 days | Not FDA-approved | 1–2 mg subcutaneously weekly |
| CJC-1295 without DAC (mod GRF 1-29) | ~30 minutes | Not FDA-approved | 100 mcg 1–3 times daily |
| Tesamorelin | 26–38 minutes | FDA-approved for HIV-associated lipodystrophy | 1–2 mg daily |
Sermorelin is not FDA-approved for human use in the United States today. CJC-1295 is not FDA-approved for human use in the United States. Tesamorelin is the only GHRH analog in this group with a current FDA approval, and it is specifically for HIV-associated lipodystrophy.
The DAC in CJC-1295 stands for Drug Affinity Complex. It binds to albumin in the blood, which protects the peptide from degradation and slows its clearance. That is why CJC-1295 with DAC is dosed weekly, while sermorelin is dosed daily or more often.
CJC-1295 without DAC does not have this albumin-binding modification. Its half-life is much closer to sermorelin's, though the four amino acid substitutions still make it more stable than natural GHRH.
These doses come from published research and are not recommendations for personal use. Always consult a healthcare professional before considering any peptide.
Common Stacks and Research Protocols
Many researchers explore combining a GHRH analog with a ghrelin mimetic like ipamorelin to produce a more natural GH pulse. A common comparison is tesamorelin vs sermorelin vs cjc-1295, because each has different half-lives and regulatory histories.
When researchers compare cjc-1295 no dac vs sermorelin, the no-DAC version is often chosen for its shorter action and ability to be dosed multiple times daily. Some protocols also look at cjc-1295 ipamorelin vs tesamorelin to decide which combination best matches a study's goals.
Stacking sermorelin directly with CJC-1295 is generally considered redundant because both work through the same GHRH receptor. A GHRH analog is more logically paired with a separate class, such as a ghrelin receptor agonist.
Ipamorelin is a selective ghrelin receptor agonist that triggers GH release without strongly affecting cortisol or prolactin in research models. Combining it with a GHRH analog can create a larger GH pulse than either peptide alone.
Timing and Forms in Research Settings
In research, the best time to take cjc 1295 ipamorelin is often debated. Many protocols administer these peptides at night to align with the body's natural nocturnal GH surge, while others use them before meals or after fasting to avoid insulin interference.
Fasting can amplify the GH response because insulin and glucose can blunt GHRH signaling. Many researchers wait at least two hours after eating before administering these peptides.
CJC 1295 capsules are not the same as injectable CJC-1295. Oral peptides face digestion and poor absorption, so capsules are generally considered less reliable for research purposes than subcutaneous injections.
Safety, Legality, and Medical Guidance
Peptides sold for research are not quality-controlled by the FDA, and they may contain impurities or incorrect amounts. Sermorelin and CJC-1295 can cause side effects such as injection-site reactions, flushing, and changes in blood sugar or hormone levels.
Because these compounds affect growth hormone, they may interact with medications for diabetes, thyroid disorders, or cancer. Anyone considering them should consult a licensed healthcare professional first.
No peptide is a cure for any condition, and self-treating with research chemicals is risky and potentially illegal. In the US, sermorelin and CJC-1295 are not approved for weight loss, anti-aging, or athletic performance.
In the US, sermorelin and CJC-1295 are not scheduled controlled substances, but they are also not approved for human use. Selling them for human consumption is illegal without FDA approval.
Legal prescription options for GH-related conditions exist, such as tesamorelin for HIV lipodystrophy or recombinant GH for confirmed deficiency. Those treatments require a doctor's oversight and monitoring.
Bottom Line
Sermorelin and CJC-1295 are both GHRH analogs, but they differ in half-life, dosing, and regulatory status. Sermorelin is short-acting and not currently FDA-approved for human use. CJC-1295 with DAC lasts for days, while CJC-1295 without DAC lasts about 30 minutes.
For research comparisons, tesamorelin is the only FDA-approved option in this class, and it is approved only for HIV-associated lipodystrophy. If you are considering these peptides for personal use, talk to a doctor and stick to legal, prescribed treatments.
Anyone researching these peptides should prioritize safety, legality, and professional medical advice over online anecdotes. The difference between sermorelin and CJC-1295 comes down to half-life and FDA status, not to one being a superior cure.
Frequently Asked Questions
Is sermorelin the same as CJC-1295?
No, sermorelin and CJC-1295 are different peptides. Sermorelin is a short-acting GHRH analog with a half-life of 10–20 minutes, while CJC-1295 with DAC lasts for days. CJC-1295 without DAC has a half-life around 30 minutes.
What is the best time to take CJC-1295 and ipamorelin?
Many research protocols dose CJC-1295 and ipamorelin at night to mimic the body's natural GH pulse during sleep. Others prefer fasting states, such as first thing in the morning or before exercise. There is no FDA-approved schedule for human use.
Is CJC-1295 FDA-approved?
No, CJC-1295 is not FDA-approved for human use in the United States. It is sold for research purposes only. Tesamorelin is the only GHRH analog in this class with an FDA approval, and it is approved specifically for HIV-associated lipodystrophy.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.